Skip to main content
SpringerLink
Log in

A lifeline for the biotech sector

  • Commentary
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

With many small biotech companies teetering at the edge of a financial precipice, the US government should act swiftly to enact tax benefits allowing a refund of net operating losses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: A greater proportion of small biotech companies in the United States are in dire financial straits than in other parts of the world.

Author information

Authors and Affiliations

  1. Mark Kessel is at Symphony Capital LLC, 875 Third Avenue, 18th floor, New York, New York 10022, USA. mark@symphonycapital.com,

    Mark Kessel

Authors
  1. Mark Kessel
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

M.K. is on the board of directors of the Biotechnology Industry Association and Symphony Capital, of which he is a managing director, and which funds drug development in collaboration with biotechnology companies.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kessel, M. A lifeline for the biotech sector. Nat Biotechnol 27, 123–124 (2009). https://doi.org/10.1038/nbt0209-123

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0209-123

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation